Lymphocyte differentiation, tolerance, metabolism and transplantation in basis for biotherapy

Our team currently develops basic and translational research on lymphocyte responses and immunotherapy. Since 2015, we originally focused on understanding the molecular mechanisms and cellular interactions responsible of the efficient activation of anti-tumor and anti-selfcytotoxic lymphocytes (CLs). We uncovered how these effector cells behave in vivo and how they are modulated in the target cell microenvironment, especially how diverse metabolism on targets affects CL reactivity. The final goal of these studies is to design new CL-based immunotherapeutic strategies for cancer and autoimmunity. Notably, some of our proposed strategies have been protected generating a private company that is close to reach the clinic.  From 2017 we have enlarged our studies to donor specific antibodies (DSA) and their role in antibody-mediated rejection after kidney transplantation, e.g. the role of NK cells on mediating rejection in this subject. In 2021, we will include in our studies liver transplantation and regeneration. In particular how hepatic metabolism, including toxic compounds, induces stress and affects immune interaction with resident liver cells. Our research allows us to generate new biotherapies and design new immunotherapies. This has gathered a large number of collaborations with private companies to develop common projects that are also in process of reaching the clinic.